MedTrace Logo

Expanded Access/Compassionate Use of Rugonersen in Patients With Angelman Syndrome

NCT07136454 · Status: AVAILABLE · Type: EXPANDED_ACCESS

Last updated 2025-08-22

No results posted yet for this study

Summary

For a patient to be considered for this EAP, they must have consented to participate in the TANGELO Optional Open-label Extension (OOE), and continue to meet the inclusion/ exclusion criteria and have not received any other investigational drug for the treatment of AS between the last dose of the TANGELO OOE and the first dose in the EAP.

The Physician making the request for expanded access considers continued treatment via the EAP with rugonersen to be a suitable treatment option for the patient under consideration.

Conditions

Interventions

DRUG

Rugonersen

Rugonersen is a selective synthetic 20-mer antisense oligonucleotide (ASO).

Sponsors & Collaborators

  • Early Access Care LLC

    collaborator UNKNOWN

  • Oak Hill Bio Ltd

    lead INDUSTRY

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07136454 on ClinicalTrials.gov